Press Releases from AFFiRiS AG (8 total)
AFFiRiS AG successfully raises €10m equity financing
• € 10m additional capital raised
• Strengthened management team, Günther Staffler appointed as Chief Technology Officer
• Noel Barrett appointed as additional member of the supervisory board
AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors and FCPB Affi GmbH. The Supervisory Board has appointed Günther Staffler as Chief Technology Officer. Noel Barrett has joined the Supervisory Board as of 15 June 2016.
In…
Vaccine Development Boosted With 10 Mio. Euros at AFFiRiS AG
Vaccine Specialist AFFiRiS AG successfully completes Financing Round
• € 10m additional capital raised
• Supervisory Board appoints Oliver Siegel as Chief Executive Officer
• Prof. Dr. Christoph Huber elected to Supervisory Board
AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors. The Supervisory Board has appointed Oliver Siegel as Chief Executive Officer and Dr. Arne von Bonin as Chief Scientific Officer. Prof. Dr. Christoph Huber has joined the…
New board member joins AFFiRiS AG
Vienna, 9. September 2014 – AFFiRiS AG today announced the appointment of Oliver Siegel as a new member of the Executive Management Board. He will take over responsibility for Business Development, Finance and Administration. The appointment of the international experienced transaction expert extends the know-how of the board with a focus on partnering and business operations. Oliver Siegel will expend his experience gained at leading international investment banks to focus…
AFFiRiS AG: ALZHEIMER'S VACCINE AD02 ALREADY IN CLINICAL PHASE II
Vienna (Austria), 23. April 2010: AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a…
Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
Vienna, November 18, 2009: AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of…
AFFiRiS AG - ENCOURAGING RESULTS FROM PHASE I STUDIES OF TWO ALZHEIMER'S CANDIDA …
Vienna, 20. October 2009: AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's vaccines AD01 and AD02, which demonstrated favourable safety and tolerability profiles. These results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals.
All 48 patients treated in these studies were given four vaccinations which were well tolerated and no serious side effects associated with…
AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds a …
Vienna, 23rd June 2009. MIG Fonds and AFFiRiS AG are this year's winners of the 2009 Venture Capital & Private Equity award competition hosted by the industry magazine Boerse-Express and Junge Industrie. The award recognised the long-standing association between the German venture fund and the Austrian biotechnology company as well as a EUR 430 million deal between AFFiRiS and GSK Biologicals.
Last Tuesday MIG Fonds and AFFiRiS AG were awarded first…
Affiris Expands Patent Portfolio for Alzheimer’s Therapies
Vienna, 27. February 2008. Affiris GmbH has secured another Europe-wide patent for an innovative method of treating Alzheimer\'s disease. This new blood-cleansing method is similar to dialysis and is designed to reduce the amount of harmful protein deposits in the brain. It is based on the AFFITOME technology established by Affiris, which was patented in October 2007 for an Alzheimer\'s vaccine. The use of this technology to cleanse the blood…
